Abstract The study of the mechanism of β-Nmethylamino-L-alanine (BMAA) neurotoxicity originally focused on its effects at the N-methyl-
Introduction
The mechanism of β-N-methylamino-L-alanine (BMAA) toxicity can be divided into two general categories: effects at the level of the cell membrane and effects through misincorporation into proteins. Actions at the cell membrane originally focused on excitotoxicity induced by activation of N-methyl-D-aspartate (NMDA) receptors (Ross et al. 1987; Weiss et al. 1989 ). However, more recent reports have cast doubt on that effect being the main mechanism of toxicity. The two most sensitive neuronal populations to BMAA toxicity are motor neurons and cholinergic neurons. The BMAA-induced death in both cases is largely blocked by α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, but not by N-methyl-D-aspartate (NMDA) antagonists (Rao et al. 2006; Liu et al. 2010) . Interestingly, both motor neurons and cholinergic neurons express large numbers of calcium-permeable AMPA receptor channels (Yin et al. 1994; Carriedo et al. 1995) . Additionally, even in conditions where NMDA receptor antagonists are protective, the protection is not complete (Ross et al. 1987; Weiss et al. 1989) . Consistent with this, we found that the non-competitive NMDA receptor antagonist MK-801 blocked about 50% of BMAA toxicity. We found that two other distinct mechanisms were also involved in the toxicity. The mGluR5 receptor antagonist 6-methyl-2-[phenylethynyl]-pyridine (MPEP), and the free radical scavenger, trolox, provided additional protection against BMAA toxicity beyond that provided by MK-801.
Furthermore, the combination of these agents provided significantly greater protection than either alone, suggesting that they were acting through distinct mechanisms . One possibility for BMAA-induced oxidative stress is competition by BMAA with cystine at system x cleading to decreased cystine uptake. We found that BMAA toxicity did involve action on system x c -, causing decreased cystine uptake leading to depletion of cellular glutathione and increased oxidative stress (Liu et al. 2009 ). These results indicate a complex set of mechanisms for BMAA toxicity. Action on system x c -appears to play a central role, both through causing oxidative stress and through releasing glutamate, which can act on various glutamate receptors to induce excitotoxicity.
The other main mechanism of BMAA-induced toxicity is through misincorporation into protein. BMAA has been shown to be incorporated into protein in cultures of human fibroblasts (MRC-5 cells), neuroblastoma (SH-SY5Y cells), and umbilical vein endothelial cells (HUVECs) The incorporation is inhibited by L-serine, suggesting that the BMAA is misincorporated in protein in exchange for L-serine. Additionally, BMAA treatment induces autofluorescence indicative of protein aggregation and apoptosis that was blocked by L-serine (Dunlop et al. 2013 ). BMAA has also been shown to be incorporated into protein in a cell-free system (Glover et al. 2014 ).
An interesting point regarding the different general mechanisms of BMAA toxicity is that system x c -can play a role in both. Our previous studies suggest that BMAA is toxic by competing with cystine at system x c -, leading to both glutathione depletion and excitotoxicity. In addition, if BMAA is transported by system x c -, it could provide a method for BMAA to enter cells where it could be misincorporated into protein. In the current study, we directly assess the mechanisms by which BMAA enters astrocytes and neurons by measuring the uptake of radiolabeled BMAA.
Methods

Materials
Timed pregnant Swiss Webster mice were obtained from Charles River Laboratories (Wilmington, DE). Serum was from Atlanta Biologicals (Lawrenceville, GA). 14 C-BMAA was from PerkinElmer (Waltham, MA). All other chemicals were obtained from Sigma (St. Louis, MO).
Cortical Cell Cultures
Cortical cell cultures containing glial and neuronal cells were prepared from fetal (15-16-day gestation) mice as previously described (Lobner 2000) . Dissociated cortical cells were plated on 24-well plates coated with poly-D-lysine and laminin in Eagles' Minimal Essential Medium (MEM, Earle's salts, supplied glutamine-free) supplemented with 5% heat-inactivated horse serum, 5% fetal bovine serum, 2 mM glutamine, and glucose (total 21 mM). Neuron-enriched cultures were prepared exactly as previously described with the addition of 10 μM cytosine arabinoside 48 h after plating to inhibit glial replication. In these cultures, <1% of cells are astrocytes (Dugan et al. 1995; Rush et al. 2010) . Astrocyte-enriched glial cultures were prepared as described for mixed cultures except they were from cortical tissue taken from post-natal day 1-3 mice (Choi et al. 1987; Schwartz and Wilson 1992; Rush et al. 2010) . Cultures were maintained in humidified 5% CO 2 incubators at 37°C. All experiments were performed on cultures DIV 13-15; at that age, neuronal cultures are defined as being mature in that they are sensitive to excitotoxicity and astrocyte cultures have formed a confluent layer of astrocytes. Culture media are not changed between plating and the experimental procedures. Mice were handled in accordance with a protocol approved by our institutional animal care committee and in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
C-BMAA Uptake
To assess 14 C-BMAA uptake, cultures were washed three times with a HEPES-buffered saline solution and then exposed to 14 C-BMAA (0.025 μCi/mL) for the indicated period of time in the HEPES-buffered saline solution. Following 14 C-BMAA exposure, all cultures were washed three times with HEPES-buffered saline solution and dissolved in 250 μL warm sodium dodecyl sulfate (0.5%). Following a 30-min period, the media were mixed by pipetting up and down several times and a 200 μL aliquot was removed and added to scintillation fluid for counting. For inhibition studies, values were normalized to 14 C-BMAA uptake in untreated controls on the same experimental plate.
Statistical Analysis
Differences between test groups were examined for statistical significance by means of one-way ANOVA followed by the Bonferroni correction post hoc test, with p < 0.05 being considered significant. N values represent individual wells on 24-well plates; data represent two independent experiments.
Results
We directly measured BMAA uptake by exposing cultures to 14 C-BMAA and assessed the uptake of radioactivity using scintillation counting. To determine the best time point to measure 14 C-BMAA uptake, we exposed mixed neuronal and astrocyte cultures to 14 C-BMAA for different periods of time. Uptake of 14 C-BMAA increased rapidly over the first 2 h before plateauing (Fig. 1) . Therefore, we choose a 2-h period of uptake for the inhibitor studies. We tested the effects of the system x c -inhibitor sulfasalazine (SSZ) and the excitatory amino acid transporter (EAAT) inhibitor threo-β-benzyloxyaspartic acid (TBOA) on both astrocyte-enriched and pure neuronal cultures. Inhibition of system x c -, but not EAATs, significantly decreased 14 C-BMAA uptake in astrocyte cultures (Fig. 2a) , while inhibition of either system x c -or EAATs significantly decreased the uptake in neuronal cultures (Fig. 2b) .
Discussion
This is the first report directly assessing the mechanisms by which BMAA is transported into astrocytes or neurons. Previous studies have addressed questions regarding transport of BMAA into the brain and the accumulation of BMAA in the brain. The transport of BMAA across the blood-brain barrier has been shown to be mediated by the large neutral amino acid carrier (Smith et al. 1992) . Subsequent studies showed that the accumulation of radiolabeled BMAA in the brain is primarily in the protein-bound fraction and that injection of radiolabeled BMAA into pregnant mice leads to the accumulation of the BMAA in the brains of fetal mice (Karlsson et al. 2009 ). Since the central nervous system uses amino acids such as glutamate and glycine as neurotransmitters, the release and uptake of amino acids within the brain must be tightly controlled. Two important systems for the regulation of amino acids in the CNS are system x c -and EAATs. Therefore, it is not surprising that both of these systems play a role in BMAA uptake. Of particular interest is the role of system x c -in BMAA transport because of the complex role that it plays in regulating neuronal death. System x c -is a sodium-independent, chloride-dependent amino acid transporter system localized in the plasma membrane. First characterized in human fibroblast cell cultures, system x c -is an antiporter that mediates the uptake of cystine into cells in exchange for exporting glutamate from the cell in a 1:1 ratio (Bannai and Kitamura 1980; Bannai 1986 ). Inhibition of system x c -mediated cystine uptake can lead to GSH depletion, oxidative stress, and cell death Murphy et al. 1989 Murphy et al. , 1990 Sagara et al. 1993b; Ratan et al. 1994) . In contrast, upregulation of system x c -can protect cells against oxidative stress-induced cell death. For example, insulin-like growth factor 1 (IGF-1) and transforming growth factor-β (TGF-β) upregulate system x c -activity and protect dental pulp cells against oxidative stress induced by dental materials (Pauly et al. 2011) . Interleukin-1β (IL-1β) upregulates system x c -activity, which protects astrocytes from oxidative stress induced by FeSO 4 or tert-butyl hydroperoxide (tBOOH) exposure (He et al. 2015) . The other main function of system x c -is the regulation of C-BMAA uptake into astrocyte-enriched cultures was partially blocked by the system x c -inhibitor sulfasalazine (SSZ) but not by the EAAT inhibitor TBOA (a), while uptake into pure neuronal cultures was partially blocked by both sulfasalazine and TBOA (b). Cultures were exposed to 14 C-BMAA for 2 h. Results are expressed as mean + SEM (n = 8) after normalizing to untreated control uptake and expressed as % control. Asterisk indicates significantly different from control C-BMAA uptake into mixed neuronal and astrocyte cultures was measured for the indicated duration. Results are in disintegrations per minute (DPM) and are expressed as mean ± SEM (n = 8) extracellular glutamate concentrations. In contrast to the possible neuroprotective mechanism of system x c -against oxidative stress, it has been shown that glutamate release via system x c -can cause excitotoxicity and lead to neuronal death (Piani and Fontana 1994; Qin et al. 2006; Domercq et al. 2007; Fogal et al. 2007; Jackman et al. 2010) .
Oxidative stress and excitotoxicity are two of the key mechanisms involved in cell death in neurodegenerative diseases (Coyle and Puttfarcken 1993; Simonian and Coyle 1996; Doble 1999) . The dual nature of system x c -suggests that it may provide antioxidant protection during times of increased oxidative stress; however, by releasing glutamate into the extrasynaptic space, it also has the potential to contribute to neuronal death through excitotoxicity. Therefore, the role of system x c -in neurodegenerative disease is likely complex and the data suggest that this is in fact the case.
Concerning amyotrophic lateral sclerosis (ALS), system x c -has been shown to be upregulated in two different mouse SOD1 mutant models of ALS (Albano et al. 2013; Mesci et al. 2015) . Interestingly, deletion of xCT in the SOD1-G37R mouse led to an earlier onset of symptoms followed by a prolonged symptomatic stage; at end stage of the disease, there were more surviving motor neurons (Mesci et al. 2015) .
To date, there are only a couple of in vivo studies that have assessed system x c -in Alzheimer's disease. In 18-month-old AßPP23 mice, expression of xCT, as assessed by western blot, was increased in the cortex. At this same time point, GLT-1 expression was decreased and there were increased levels of extracellular glutamate . Transgenic mice expressing human APP and wild-type mice injected with Aβ 1-40 had increased xCT mRNA levels in microglia in amyloid plaques (Qin et al. 2006) .
Studies regarding the effects of system x c -in Parkinson's disease models have provided mixed results. In a hemiParkinson rat model, injection of 6-hydroxydopamine (6-OHDA) caused an ipsilateral increase in xCT protein in the striatum (Massie et al. 2008) and dopaminergic neurons in the substantia nigra pars compacta were protected from 6-OHDA injection in xCT − / − mice compared to wild-type mice (Massie et al. 2011 ). These results suggest that system x c -may contribute to the neurodegeneration seen in PD. However, the anti-epileptic drug levetiracetam increased xCT expression in striatal astrocytes and significantly decreased dopaminergic cell loss in mice injected with 6-OHDA (Miyazaki et al. 2016) .
The mixed results regarding the beneficial or damaging effects of system x c -in neurodegenerative diseases are not surprising considering its dual effects. However, two factors are important concerning the role of system x c -in the toxicity of BMAA. First, in each of the diseases described earlier, there is an upregulation of system x c -. Whether the upregulation is beneficial or damaging under conditions where BMAA is not present appears to vary. Second, BMAA negates the beneficial effects of system x c -by blocking cystine uptake but promotes the damaging effect by driving glutamate release. Therefore, in conditions of upregulation of system x c -, the presence of BMAA is likely to be even more damaging than normal.
Another important effect that we observed was that blocking EAATs also partially blocked BMAA uptake into neurons. This result is of interest in two ways. First, it provides another mechanism for BMAA to enter neurons. Second, it suggests the possibility that BMAA may competitively inhibit glutamate uptake. If BMAA both drives glutamate release by acting on system x c -and inhibits glutamate uptake by EAATs, this could lead to high extracellular glutamate concentrations and excitotoxicity. Therefore, there are a number of reasons to believe that BMAA acting at the level of amino acid transporters on astrocytes and neurons plays a role in its potential involvement in neurodegenerative diseases.
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